Tiziana Life Sciences Ltd
corporate_fare Company Profile
Tiziana Life Sciences Ltd (NASDAQ:TLSA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 25 items for TLSA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-30, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 8/10, with 4 rated 8 or above. Recent SEC coverage for TLSA spans 6-K, 4, 20-F.
Recent high-impact activity:
- Tiziana Seeks FDA Orphan Drug Designation for Intranasal Foralumab in MSA
- Tiziana Files for FDA Orphan Drug Designation for Intranasal Foralumab in MSA
- Tiziana Doses First Three Patients in Phase 2a ALS BANYAN Trial of Intranasal Foralumab
- Tiziana Doses First ALS Patients in Phase 2a BANYAN Trial of Intranasal Foralumab
- Tiziana Completes Last Patient Visit in Phase 2a INFORM-MS Trial; Topline Data Due October
Financial Snapshot
Short Interest & Short Volume
3.54 days to coverFINRA reported short interest of 1,733,862 shares in TLSA as of the September 15, 2026 settlement, a 2.0% increase from the prior period — about 3.5 days to cover at its recent average daily volume. On October 2, 2026, 49.4% of TLSA volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for TLSA, detected from its recent SEC filings.
Auditors Issue Going Concern Warning · Secured $8.6M in Registered Direct Offering
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →
Insider Transactions
TLSA files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.